Metagenomi (NASDAQ:MGX) Rating Lowered to “Sell” at Wall Street Zen

Metagenomi (NASDAQ:MGX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Metagenomi Price Performance

Shares of NASDAQ MGX opened at $1.41 on Friday. Metagenomi has a 12-month low of $1.23 and a 12-month high of $3.95. The company has a market capitalization of $52.86 million, a PE ratio of -0.59 and a beta of 0.45. The firm’s 50-day moving average is $1.56 and its two-hundred day moving average is $1.91.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.The business had revenue of $3.91 million for the quarter, compared to analysts’ expectations of $7.33 million. On average, analysts forecast that Metagenomi will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Metagenomi

Several hedge funds have recently modified their holdings of MGX. BNP Paribas Financial Markets grew its holdings in shares of Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after buying an additional 14,389 shares in the last quarter. Bank of America Corp DE raised its position in shares of Metagenomi by 508.5% in the third quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after buying an additional 15,682 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Metagenomi during the fourth quarter valued at approximately $53,000. Quadrature Capital Ltd purchased a new position in shares of Metagenomi during the fourth quarter valued at approximately $55,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Metagenomi during the third quarter worth approximately $64,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.